Fujita Health University Haneda Clinic to introduce Tumor Portrait test by BostonGene

image credit- shutterstock

BostonGene, a leading provider of AI-based molecular immune profiling solutions, has launched its cancer genome profiling test, Tumor Portrait, at Fujita Health University Haneda Clinic.

This comprehensive genomic test combines DNA and RNA sequencing results with a patient's clinical profile, selected treatment options, and available clinical trials into one simple report to identify actionable mutations, microenvironment characteristics, and biomarkers that predict treatment outcomes to guide cancer treatment.

First introduced in Cancer Cell in 2021, the Tumor Portrait test reveals cancer genetic mutations, interactions with the immune system, and biomarkers that predict response to various therapies, and suggests personalized treatment. It is a CLIA-certified, CAP-accredited, and New York State-approved clinical test, and is widely used by leading academic and oncology clinics across the United States.

At Fujita Health University Haneda Clinic, we use this test to quickly perform molecular diagnosis, including recurrence, and propose more effective treatments. Based on the results, patients can access cutting-edge treatments.

Yukimasa Shiotsu, President and CEO of BostonGene Japan, said, "We are proud to partner with Fujita Health University and Fujita Health University Haneda Clinic to make the BostonGene Tumor Portrait test available to more cancer patients in Japan. This partnership is an important step in advancing precision medicine, enabling more patients to benefit from personalized treatments that improve outcomes and enhance quality of life."